anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, gastroenterology. SUBSTANCE: preparations are prescribed based on gastric secretion data. Microcirculation in of mucosa pyloro-duodenal region is assayed by endoscopy Doppler fluometry additionally. Actovegin is prescribed in the presence of increased secretion and decreased microcirculation and H2-antagonists of histamine receptors are prescribed additionally to patients of age before 50 years and omeprazole is prescribed to patients of age above 50 years. Only actovegin is prescribed to patients with normal secretion and decreased microcirculation. Preparations enhancing reparative processes are prescribed to patients with normal secretion and microcirculation. Method ensures to treat patients based on pathogenetic specificities of disease course using minimal amount of drugs. EFFECT: improved method of treatment. 3 ex
In this study, 120 subjects who already suffered from headache symptoms (such as dizziness, heavy head, lightheadedness, head fullness, migraine) were treated with acupuncture at acupuncture points, and the pulse diagnosis instrument was used to capture the subjects' symptoms during acupuncture. The pulse waves before and after are collected, compared and analyzed to complete this test.

After the subjects are accepted, they will go to the Acupuncture and Traumatology Department of the Department of Traditional Chinese Medicine of Chang Gung Memorial Hospital (Taoyuan Branch) at an agreed time for health education and filling out questionnaires. After filling out the questionnaire, participants can reserve a time for the test.

One person is tested each time, and each test lasts 70-80 minutes. Pulse waves are collected for 20 minutes before and after the test. The acupuncture treatment plan for each subject in this study was based on traditional Chinese medicine theory and published literature. The acupuncture points selected were bilateral Cuanzhu, Taiyang, Tianzhu, Fengchi, Baihui, Hegu, Neiting, Zusanli, Waiguan, and Zulin. Qi, Houxi, Shenmai, Taichong. The doctor will select the above 4-6 acupoints according to the disease. It is divided into an acupuncture group and a sham acupuncture group. Before the experiment, first fill out the questionnaire. This trial is divided into an acupuncture group and a sham acupuncture group. A crossover design is adopted. 50% of the subjects will be assigned to the acupuncture group first. Then they will be connected to the sham acupuncture group, and the other 50% of the subjects will be assigned to the sham acupuncture group first and then the acupuncture group. Each group will last for two weeks, and acupuncture will be performed twice a week at the set acupuncture points. The first group of acupuncture will end. , will be interrupted for two weeks, and then another set of tests will be conducted, and then the patient will go to Chang Gung Memorial Hospital Taoyuan Branch for the final scale and quality of life questionnaire. The total trial period was eight weeks.

While undergoing the test, try to avoid taking Chinese and Western medicines and alcoholic beverages to avoid interfering with the study. (If participants usually take antihypertensive drugs and heart drugs, participants can continue to take them.) After the test, participants should drink more warm water and get enough rest. Do not take a shower or touch or drink cold things.
The invention discloses a compound cotinus coggygria oral solution and a preparation method thereof. The oral solution is prepared from the following components: 250-350g of cotinus coggygria, 150-250g of schisandra chinensis, 250-350g of sedum sarmentosum, 150-250g of Chinese wolfberry fruits, 200-300g of cape jasmine and 200-300g of Chinese dates. The compound cotinus coggygria oral solution is prepared by using cotinus coggygria as a monarch drug, schisandra chinensis and sedum sarmentosum as ministerial drugs, Chinese wolfberry fruits and cape jasmine as assistant drugs and Chinese dates as a guide drug, and the medicinal materials are combined to achieve the effects of drying dampness, clearing heat, removing jaundice and lowering transaminase to treat acute icteric hepatitis and chronic hepatitis. Clinical observation proves that the compound cotinus coggygria oral solution has a remarkable curative effect for treating jaundice hepatitis and anicteric hepatitis. By adopting a refined production process, the extraction of effective ingredients of medicinal materials can be improved, the preparation stability is guaranteed, and treatment effect reduction and occurrence of adverse response caused by poor quality of the preparation can be reduced. The preparation mode of the oral solution has the advantages of less taking dosage, quick absorption and stable quality.
Ovarian cancer is a lethal gynecologic cancer mostly diagnosed in an advanced stage with an accumulation of ascites. Interleukin-6 (IL-6), a pro-inflammatory cytokine is highly elevated in malignant ascites and plays a pleiotropic role in cancer progression. Mitochondria are dynamic organelles that undergo fission and fusion in response to external stimuli and dysregulation in their dynamics has been implicated in cancer progression and metastasis. Here, we investigate the effect of IL-6 on mitochondrial dynamics in ovarian cancer cells (OVCs) and its impact on metastatic potential. Treatment with IL-6 on ovarian cancer cell lines (SKOV3 and PA-1) led to an elevation in the metastatic potential of OVCs. Interestingly, a positive association was observed between dynamin-related protein 1 (Drp1), a regulator of mitochondrial fission, and IL-6R in metastatic ovarian cancer tissues. Additionally, IL-6 treatment on OVCs was linked to the activation of Drp1, with a notable increase in the ratio of the inhibitory form p-Drp1(S637) to the active form p-Drp1(S616), indicating enhanced mitochondrial fission. Moreover, IL-6 treatment triggered the activation of ERK1/2, and inhibiting ERK1/2 mitigated IL-6-induced mitochondrial fission. Suppressing mitochondrial fission through siRNA transfection and a pharmacological inhibitor reduced the IL-6-induced migration and invasion of OVCs. This was further supported by 3D invasion assays using patient-derived spheroids. Altogether, our study suggests the role of mitochondrial fission in the metastatic potential of OVCs induced by IL-6. The inhibition of mitochondrial fission could be a potential therapeutic approach to suppress the metastasis of ovarian cancer.
This study seeks to characterize the mRNA profile of TNBC in Nigeria and compare to a reference population in Nova Scotia. Insight into the unique tumor-immune profile of TNBC in Nigeria and the link between the West African-linked Duffy-antigen receptor for chemokines (DARC) and TNBC subtype will be explored for the first time.

Fresh frozen TNBC tissue from the African Research Group for Oncology (ARGO) and Dalhousie/NSHA breast cancer biobanks' will be processing and analyzed by the Genomics Core Facility at Dalhousie University. Clinical data is prospectively collected with specimen acquisition in the ARGO biobank. For the Dalhousie /NSHA biobank, clinical data will be retrospectively gathered from the medical record and migrated to an electronic database for prospective collection during the course of the study. Both cohorts of specimens will be run through DNA and whole transcriptome (mRNA) sequencing on the TSO500 platform (Illumina Ulc.). The tumor-immune microenvironment will be compared between cohorts and by mRNA cluster using the transcriptional signatures for 22 leukocyte populations and immune-regulating proteins CTLA-4 and PD-L1. Finally, tumor expression of DARC will be generated from the transcriptome data that will allow for an assessment of the relationship between DARC expression, TNBC mRNA clusters, and sociodemographic variables (i.e. race/ancestry, gender). Whole transcriptome data from The Cancer Genome Atlas will be pulled as the third cohort, including 55 TNBC specimens from African Americans.
Neonatal jaundice (NNJ) continues to be a significant global problem affecting over 80% of neonates while severe neonatal jaundice affects at least 481,000 neonates annually. Jaundice and jaundice related complications like Kernicterus Spectrum Disorder (KDS) are gaining recognition among the world's health policy leaders as an important area for further research and development. The long-term sequelae of KSD include choreoathetoid cerebral palsy, sensorineural hearing loss, and upward gaze palsy. KSD is irreversible resulting in a lifetime of physical, emotional, social and economic challenges. Access to cost-effective methods of improving pediatric jaundice care along with improved circumferential (full body) illumination technologies is an affirmed objective of the AAP (American Academy of Pediatrics). The investigators hypothesize that unused therapy light (irradiance) surrounding the neonate using an existing single-lamp bank phototherapy (PT) device is sufficient in quantity and if redirected onto the patients untreated or poorly illuminated skin surfaces, it will accelerate metabolism and excretion of bilirubin. This PT ring device redirects unused phototherapy light sideways onto the neonate body using an open-faced ring approach. The technology will illuminate previously unexposed and poorly exposed skin regions where treatable bilirubin exists. The device is superior to current PT devices in that it converts existing waste light into treatment efficacy while integrating into existing overhead lamp systems offsetting the purchase of secondary devices that are often unaffordable and create hospital complexity, cost and inefficiency issues. A further benefit of the device will be reduced ambient blue-light spillover in patient care areas, an ongoing concern for medical staff.
One forearm of one of three subjects will be randomized to the scale "control" forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale "control" forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining "randomized" forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the "control" forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study.
Participants and one family member that lives with them will be provided catered LFD meals for 8 consecutive weeks consisting of daily breakfast, lunch, dinner and snacks. In addition, the participant and their family member will receive 12 consecutive weeks of Dyadic Psychological Support (DPS).
Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
The present disclosure relates to several types of finger vein sensor. In certain embodiments, the finger vein sensor includes: an image sensor, and an infrared light source. Image sensor captures infrared image of finger vein pattern of a finger of a target human. The image sensor faces down and is positioned at top of finger vein sensor. The infrared light source may include a predetermined number of infrared light-emitting diodes (LED), and they are arranged in one or more rows and one or more columns and positioned at bottom of finger vein sensor. The finger is positioned between infrared light source and image sensor. The infrared light from the infrared light source irradiates the finger vertically from the bottom to generate the infrared image of finger vein pattern of the finger on the image sensor, and the image sensor captures the infrared image of finger vein pattern of the finger.
Desiccation is a fundamental challenge confronted by all terrestrial organisms, particularly insects. With a relatively small body size and large surface-to-volume ratio, insects are susceptible to rapid evaporative water loss and dehydration. To counter these physical constraints, insects have acquired specialized adaptations, including a hydrophobic cuticle that acts as a physical barrier to transpiration. We previously reported that genetic ablation of the oenocytes - specialized cells required to produce cuticular hydrocarbons (HCs) - significantly reduced survivorship under desiccative conditions in the fruit fly, Drosophila melanogaster. Although increased transpiration - resulting from the loss of the oenocytes and HCs - was hypothesized to be responsible for the decrease in desiccation survival, this possibility was not directly tested. Here, we investigated the underlying physiological mechanisms contributing to the reduced survival of oenocyte-less (oe-) flies. Using flow-through respirometry, we show that oe- flies, regardless of sex, exhibited an increased rate of transpiration relative to wild-type controls, and that coating oe- flies with fly-derived HC extract restored the rate to near-wild-type levels. Importantly, total body water stores, including metabolic water reserves, as well as dehydration tolerance, measured as the percentage of total body water lost at the time of death, were largely unchanged in oe- flies. Together, our results directly demonstrate the critically important role played by the oenocytes and cuticular HCs to promote desiccation resistance.
Part A1 will evaluate ART4215 monotherapy administered in 21 day cycles. Up to 90 participants will participate in this dose escalation arm.
Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.
Local anesthesia with conventional syringe Procedure: Local anesthesia with conventional syringe + xylitol sublingual tablet Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.
In a process for forming a hydrogel, a precursor crosslinkable through disulfide bonds for forming the hydrogel is provided in a solution. The precursor comprises a branched molecular structure, which comprises a plurality of branches. At least three of the branches each comprises a disulfide bond. The pH in the solution is adjusted to initiate thiol-disulfide exchange in the precursor, thus crosslinking the precursor through disulfide bonds formed by thiol-disulfide exchange. After the precursor is sufficiently crosslinked to form a hydrogel, the pH in the solution is adjusted to inhibit further thiol-disulfide exchange in the hydrogel. Further, a hydrogel matrix may comprise a polymer substantially crosslinked through disulfide bonds. The polymer may comprise a hydrophobic poly(amido amine) core and an amino-functionalized hydrophilic shell.
Dextroamphetamine sulfate tablets are a Schedule II controlled substance. 

Amphetamines have been extensively abused. Tolerance, extreme psychological dependence and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. 

Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. This is rare with oral amphetamines.
Parainfluenza virus types 1 to 4 (PIV1 to PIV4) are important human pathogens that cause upper and lower respiratory tract infections, particularly in infants and children. The claimed invention is directed toward novel methods for the inhibition of parainfluenza virus transmission to a cell involving the administration of synthetic peptide fusion inhibitors. These inhibitors are derived from the parainfluenza virus and vary in length between 16 to 39 amino acids. The peptides were identified by screening for the presence of fusion inhibitory motifs (e.g., ALLMOTI5, 107x178x4, and PLZIP) within the parainfluenza virus genome. A number of peptides were identified and their fusion inhibitory activities ascertained. These peptides should provide useful antiviral agents.
The safety and efficacy of Kepivance in decreasing the incidence and duration of severe oral mucositis in patients with hematologic malignancies (NHL, Hodgkin's disease, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, or multiple myeloma) receiving myelotoxic therapy requiring hematopoietic stem cell support, were established in a randomized placebo-controlled clinical trial of 212 patients (Study 1) and a randomized, schedule-ranging, placebo-controlled clinical trial of 169 patients (Study 2). 

In Study 1, patients received high-dose cytotoxic therapy consisting of fractionated total-body irradiation (TBI) (12 Gy total dose), high-dose etoposide (60 mg/kg), and high-dose cyclophosphamide (100 mg/kg) followed by hematopoietic stem cell support. Patients were randomized to receive either Kepivance (n = 106) or placebo (n = 106). Kepivance 60 mcg/kg was administered as a daily intravenous injection for 3 consecutive days prior to initiation of cytotoxic therapy and for 3 consecutive days following infusion of hematopoietic stem cells. The major efficacy outcome was the number of days during which patients experienced severe oral mucositis (Grade 3/4 on the WHO [World Health Organization] scale) 1. Other analyses included the incidence, duration, and severity of oral mucositis and the use of opioid analgesia. There was no evidence of a delay in time to hematopoietic recovery in patients who received Kepivance as compared to patients who received placebo. The results of Study 1 are presented in Table 2 and Figure 1. 

Figure 1: Study 1 Incidence of Oral Mucositis by Maximum Grade WHO Oral Mucositis Scale

Study 2 was a randomized, multi-center, placebo-controlled trial comparing varying schedules of Kepivance. All patients received high-dose cytotoxic therapy consisting of fractionated TBI (12cGy total dose), high-dose etoposide (60 mg/kg), and high-dose cyclophosphamide (75-100 mg/kg) followed by hematopoietic stem cell support. The results for Study 1 were supported by results observed in the subset of patients in Study 2 who received the same dose and schedule of Kepivance administered in Study 1. One arm of Study 2 that included patients who received Kepivance for 3 consecutive days prior to initiation of cytotoxic therapy, a dose given on the last day of TBI prior to etoposide, and for 3 consecutive days following infusion of hematopoietic stem cells was prematurely closed by the Safety Committee for lack of efficacy and a trend towards increased severity and duration of oral mucositis as compared to placebo-treated patients. The Safety Committee attributed the safety finding to Kepivance having been administered within 24 hours of chemotherapy, which resulted in an increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period [see Dosage and Administration ( 2.1) and Drug Interactions ( 7)]. 

* * *

1
    WHO Oral Mucositis Scale: Grade 1 = soreness/erythema; Grade 2 = erythema, ulcers, can eat solids; Grade 3 = ulcers, requires liquid diet only; Grade 4 = alimentation not possible.
On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
Automated neuromuscular blockade monitoring (ATP). TOF and PTC stimulations are regularly performed, and PTC is systematically performed if TOF = 0/4. If PTC = 10/10, a TOF stimulation is automatically performed.
In this three-arm, pragmatic, prospective, multicentre, double blind, randomised sham-controlled trial of approximately 4 years duration, 400 patients with chronic moderate to severe anterior knee pain (\>12 months) refractory to conventional treatments will be included. Two groups of chronic knee pain patients will be enrolled depending on the aetiology of knee pain: OA and PPSP. Each patient will undergo a run-in period of 1 to 3 months depending on the previous treatments of the patient. A run-in period is added to the trial to guarantee that conservative treatment is performed in an optimal way before randomisation. In each group (osteoarthritis and persistent post-surgical pain), non-responders to the run-in period will be randomly allocated to a conventional RF intervention of the genicular nerves, a cooled RF intervention of the genicular nerves or a sham procedure in a 2:2:1 ratio. The patients will be followed up for a period of 2 years.
Compositions comprise, as active ingredient having anthelmintic and antibacterial properties, a salicylanilide derivative of the general formula wherein R 1 is a hydrogen atom or an acyl radical Y is a halogen atom or a hydroxy, haloalkyl, C 1-5 alkyl, C 1-5 alkoxy or nitro radical each of X and X 1 is a halogen atom or an alkyl, haloalkyl, alkoxy, halogenated alkoxy, halogenated alkylthio, nitro, cyano, hydroxy, amino, alkylamino or alkanoylamino radical Q is an oxygen or sulphur atom or a sulphinyl, sulphonyl, alkylene, alkyleneoxy, carbonyl or carbamoyl radical R is a hydrogen atom, a C 1-5 alkyl radical or an alkanoic acid residue and each n is 0, 1, 2 or 3, ring C being linked to either the 3- or 4-position of ring B or a pharmaceutically acceptable salt thereof, together with an inert carrier, diluent or coating and, optionally, an effective amount of a second anthelmintic or antibacterial compound. The compositions may take the form of an animal feedstuff, feed premix, tablet, bolus, capsule, drench, germicide, deodorant, disinfectant, dusting powder, cream, lotion, cosmetic or parenterally administerable solution. Specified pharmaceutically acceptable salts are those formed with metals, e.g. sodium, potassium, calcium, copper and iron, and amines, e.g. pyridine, piperazine, methylamine and ethanolamine. Examples of a second anthelmintic compound are thiabendazole, tetramisol, an organo-phosphorus compound, piperazine, phenothiazine or certain antimony compounds. Examples of a second antibacterial compound are sulphonamides, certain penicillin preparations or certain antibiotics.
PCT No. PCT/CA93/00378 Sec. 371 Date Jul. 12, 1994 Sec. 102(e) Date Jul. 12, 1994 PCT Filed Sep. 15, 1993 PCT Pub. No. WO94/06296 PCT Pub. Date Mar. 31, 1994The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of -1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.